AKT1 and cancer: Dysregulation of PI3K signaling, often through mutations in PIK3CA, loss of PTEN, or hyperactivation of AKT, is implicated in various cancers, including breast, ovarian, and colorectal cancers, as well as cutaneous malignancies [75,76].